Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AtriCure (ATRC) Common Equity (2016 - 2025)

AtriCure (ATRC) has disclosed Common Equity for 16 consecutive years, with $491.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity rose 6.72% to $491.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $491.9 million, a 6.72% increase, with the full-year FY2025 number at $491.9 million, up 6.72% from a year prior.
  • Common Equity was $491.9 million for Q4 2025 at AtriCure, up from $476.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $491.9 million in Q4 2025 to a low of $385.1 million in Q2 2021.
  • A 5-year average of $457.7 million and a median of $462.3 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: soared 72.08% in 2021, then decreased 7.81% in 2022.
  • AtriCure's Common Equity stood at $483.8 million in 2021, then dropped by 5.58% to $456.8 million in 2022, then grew by 2.06% to $466.2 million in 2023, then fell by 1.12% to $461.0 million in 2024, then increased by 6.72% to $491.9 million in 2025.
  • Per Business Quant, the three most recent readings for ATRC's Common Equity are $491.9 million (Q4 2025), $476.5 million (Q3 2025), and $464.5 million (Q2 2025).